BACKGROUND: Lynch syndrome (LS) is the most common hereditary cause of colorectal cancer (CRC) and endometrial cancer (EC). Screening of all CRCs for LS is currently recommended, but screening of ECs is inconsistent. The objective of this study was to determine the added value of screening both CRC and EC tumors in the same population. METHODS: A prospective, immunohistochemistry (IHC)-based screening program for all patients with newly diagnosed CRCs and ECs was initiated in 2011 and 2013, respectively, at 2 centers (primary and tertiary). Genetic testing was recommended for those who had tumors with absent mutS homolog 2 (MSH2), MSH6, or postmeiotoic segregation increased 2 (PMS2) expression and for those who had tumors with absent mutL homolog 1 (MLH1) expression and no v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation or MLH1 promoter methylation. Amsterdam II criteria, revised Bethesda criteria, and scores from prediction models for gene mutations (the PREMM 1,2,6 and PREMM 5 prediction models) were ascertained in patients with LS. RESULTS: In total, 1290 patients with CRC and 484 with EC were screened for LS, and genetic testing was recommended for 137 patients (10.6%) and 32 patients (6.6%), respectively (P 5.01). LS was identified in 16 patients (1.2%) with CRC and in 8 patients (1.7%) with EC. Among patients for whom genetic testing was recommended, the LS diagnosis rate was higher among those with EC (25.0% vs 11.7%, P 5.052). The Amsterdam II criteria, revised Bethesda criteria, and both PREMM calculators would have missed 62.5%, 50.0%, and 12.5% of the identified patients with LS, respectively. CONCLUSIONS: Expanding a universal screening program for LS to include patients who had EC identified 50% more patients with LS, and many of these patients would have been missed by risk assessment tools (including PREMM 5 ). Universal screening programs for LS should include both CRC and EC. Cancer
INTRODUCTION
Lynch syndrome is the most common hereditary cause of colorectal cancer (CRC) and endometrial cancer (EC). [1] [2] [3] Recognizing LS is critical because of the markedly elevated risks of cancer in affected family members. Adherence to a tailored screening program can reduce these cancer risks. 1, 2 The diagnosis of LS syndrome is established by the detection of a germline mutation in 1 of the 4 DNA mismatchrepair (MMR) genes (mutL homolog 1 [MLH1], mutS homolog 2 [MSH2], mutS homolog 6 [MSH6], or postmeiotoic segregation increased 2 [PMS2]) or the epithelial cell-adhesion (EPCAM) gene. Because genetic testing remains relatively costly and cumbersome, strategies have been proposed to offer genetic testing only to those who have clinical features that are highly suggestive of LS. The Amsterdam or Bethesda clinical criteria were traditionally used, but their performance has proven to be inadequate. 1, 2, 4 On the other end of the spectrum, universal screening strategies that test all colorectal tumors with immunohistochemistry (IHC) for the 4 MMR proteins have gained favor as an easily implementable process that can maximize the detection of unrecognized LS. [5] [6] [7] Calculators that estimate the risk of a germline mutation based on clinical features and family history also have been proposed. 2, 6, [8] [9] [10] Multiple societies currently recommend universal screening for patients with newly diagnosed CRC using IHC or microsatellite instability testing, and this is now standard in many institutions. 1, 2 However, this strategy has not been widely adopted for other Lynch-associated tumors. 11, 12 In particular, universal screening of patients who have EC, which is the second most common malignancy in LS, is not routinely performed; and a recent position statement from the Society of Gynecologic Oncology recognizes universal screening of patients with EC as an option but does not broadly recommend its implementation. 13 In an effort to maximize the detection rate of LS in the general population, we sought to determine whether screening of all ECs would improve the detection rate of LS when added to a universal screening program of CRCs. The performance of such a combined screening program in a real-world setting has not been previously defined. In particular, it is uncertain whether such a combined program would be redundant and would only identify the same LS families. To the best of our knowledge, this is the first prospective program measuring the added value of universal screening of all ECs compared with an analysis of CRCs alone in the same population.
MATERIALS AND METHODS

Study Group and Design
An IHC-based universal screening program for LS was implemented for all patients who had newly diagnosed CRC and EC at 2 sites: Massachusetts General Hospital (a tertiary care center in Boston, MA) and North Shore Medical Center (a community hospital in Danvers, MA). When indicated, a recommendation for genetic counseling and evaluation for LS was made to the patient's physician.
The data collected and analyzed included demographics, scores on the PREMM 1,2,6 and PREMM 5 10 prediction models for gene mutations, results of tumor testing, and the outcomes of genetic evaluations. This study was approved by the institutional review board of each institution.
IHC-Based Tumor Testing and Identification of Candidates for Genetic Counseling and Testing
Patients with EC and those with CRC were screened universally for LS using IHC staining for 4 MMR proteins (MLH1, MSH2, MSH6, and PMS2), as previously described.
14 Briefly, tumors with absent MSH2, MSH6, or PMS2 expression were considered suspicious for LS, and further genetic workup was indicated. In those who had tumors with absent or faint MLH1 staining, additional tumor testing was performed to identify somatic MLH1 alterations, including MLH1 promoter methylation for endometrial tumors and MLH1 promoter methylation combined with v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation for colorectal tumors. MLH1 promoter methylation and BRAF mutation testing were performed as previously described. 14 Patients who had endometrial tumors that tested positive for MLH1 promoter methylation and those who had colorectal tumors that tested positive for both MLH1 promoter methylation and BRAF mutation were considered sporadic, and no further counseling was recommended. Further genetic counseling and testing were recommended for those who had all other tumors with loss of MLH1 staining.
Genetic Testing
Genetic counseling with a licensed genetic counselor was provided, and genetic testing for LS was offered as clinically indicated. Genetic testing was performed in commercial Clinical Laboratory Improvement Amendmentsapproved laboratories for those who consented. All patients with a germline mutation were evaluated for fulfillment of the Amsterdam II and revised Bethesda criteria and for their PREMM 1,2,6 scores (cutoff score, >5%) and PREMM 5 scores (cutoff score, 2.5%).
Statistical Analysis
Unless indicated otherwise, continuous variables are presented as means 6 standard deviations, and dichotomous variables are presented as proportions with 95% confidence intervals (CIs) where applicable. Comparisons of the means of 2 samples were performed using nonpaired 2-sample t tests, and dichotomous outcomes were compared using chi-square tests or Fisher exact tests based on group size. P values .05 were considered statistically significant. Statistical analysis was performed using Stata (version 14.1; StataCorp LP, College Station, TX).
RESULTS
Study Group
In total, 1774 patients were screened for LS ( (Fig. 1) . Specific IHC staining results are outlined in Supporting Table 1 . In both groups, the most common pattern was the absence of MLH1 and PMS2 staining (17.6% and 15.4% of all patients with EC and CRC, respectively; P 5 NS).
Among the 206 patients who had CRC tumors with abnormal MLH1 staining, 157 completed both MLH1 methylation and BRAF mutation testing. Of these, 106 patients (67.5%; 95% CI, 59.6%-74.8%) tested positive for both, 22 (14%; 95% CI 9%-20.4%) tested negative for both, and 29 (18.5%; 95% CI, 12.7%-25.4%) had discordant results. Of the 29 patients who had discordant results, 26 had tumors that were positive for MLH1 promoter methylation with wild-type BRAF, and 3 tested negative for MLH1 promoter methylation but carried a BRAF mutation (V600E in 2 patients and K601E in the third patient). The 106 tumors with absent MLH1 and Other histologic types of endometrial tumors included undifferentiated (n 5 10), clear cell carcinoma (n 5 2), mixed serous and clear cell carcinoma (n 5 2), mixed endometrioid and clear cell carcinoma (n 5 2), mucinous adenocarcinoma (n 5 2), low-grade mullerian adenosarcoma (n 5 1), and mixed endometrioid, serous, and undifferentiated carcinoma (n 5 1). c Other colorectal cancers included 1 patient who had focally subnuclear cytoplasmic clearing and patchy foci suggestive of neuroendocrine differentiation and 1 invasive adenocarcinoma, colonic type, in a urinary bladder from a patient who had previously undergone cecal augmentation of the bladder and subsequently developed colonic metaplasia of the bladder.
PMS2 expression that tested positive for both MLH1 methylation and BRAF mutation were considered sporadic, and further testing was recommended for all others. In total, 100 patients who had tumors with absent MLH1 expression and 37 who had tumors with MSH2, MSH6, or PMS2 loss were referred for genetic evaluation (137 of 1290 patients; 10.6%). Among 86 patients who had EC tumors with MLH1 loss on IHC, 75 (87%) tested positive for MLH1 promoter methylation and were considered sporadic. Further genetic testing was recommended for the remaining 11 patients who had tumors with absent MLH1 staining and for 21 patients who had tumors with MSH2, MSH6, or PMS2 loss. Overall, 32 of 484 patients (6.6%) with EC were referred for genetic counseling.
Detection of LS by Genetic Testing
Among the 137 patients with CRC and 32 patients with EC for whom genetic testing was recommended, 73 with CRC and 17 with EC attended genetic counseling, yielding nearly identical attendance rates (53.3% and 53.1%, respectively). Among those who attended a counseling session, 58 of 73 patients with CRC (79.5%) and 16 of 17 patients with EC (94.1%) pursued genetic testing (P 5 NS).
A diagnosis of LS was made in 24 individuals. Sixteen of these patients were identified through the CRC screening program, and 8 were identified through the EC screening program. The addition of EC screening to a CRC screening program increased the number of LS families diagnosed by 50%. The overall detection rate of LS in Figure 1 . The results of universal screening for Lynch syndrome (LS) are illustrated in patients with colorectal cancer and endometrial cancer. BRAF indicates v-Raf murine sarcoma viral oncogene homolog B; IHC, immunohistochemistry; Meth., methylation; MLH1, mutL homolog 1; MMR, mismatch repair; MSH2, mutS homolog 2; MSH6, mutS homolog 6.
our study population was 1.4% (95% CI, 0.9%-2%), with a rate of 1.2% (95% CI, 0.8%-2%) in patients with CRC and 1.7% (95% CO. 0.8%-3.3%) in patients with EC (P 5 NS). Among the subset of patients for whom genetic testing was recommended, the rate of LS diagnosis was higher among those with EC (8 of 32 patients; 25%) compared with those who had CRC (16 of 137 patients; 11.7%; P 5 .052) (Fig. 2) . Four patients (3 with CRC and 1 with EC) were members of previously identified LS families and were correctly flagged by universal screening, yielding a detection rate of new LS cases for this period of 1.1%. The average number of patients who had LS identified by the program on an annual basis was 2.7 per year among those with EC and 3.2 per year among those with CRC.
Clinical features of the patients who had LS identified in both programs are summarized in Tables 2 and 3 . Patients with LS were younger than those without LS at the time of cancer diagnosis in both the EC group (mean age, 56 vs 64 years [P 5 .06]; median age, 54 vs 65 years; age range, 45-78 vs 22-91 years, respectively) and the CRC group (mean age, 55 vs 66 years [P < .01]; median age, 53 vs 66 years; age range, 32-85 vs 10-100 years, respectively). Among the patients with EC, germline MMR mutations were identified most frequently in MSH6 (n 5 4), followed by MLH1 (n 5 2), and MSH2 (n 5 2). No PMS2 mutations were identified in patients with EC. Among the patients with CRC, germline mutations were identified most frequently in MLH1 (n 5 6), followed by PMS2 (n 5 4), MSH2 (n 5 3), and MSH6 (n 5 3). None of the 8 patients with EC who had LS identified were previously diagnosed with CRC, and none of the families identified through universal screening of EC were related to any of those identified through universal CRC screening. The variants of unknown significance that were identified are described in Supporting Table 2 .
Fifty patients who had Lynch-like syndrome (MMR deficient; defined as abnormal IHC findings and a negative workup for MMR gene mutations) were identified (42 with CRC and 8 with EC). Their mean age was 60.6 6 14.6 years. It is noteworthy that, among the 29 patients who had CRC tumors with absent MLH1 staining and discordant results between MLH1 promoter methylation and BRAF mutation analysis, no germline mutation was identified. Specifically, all 3 patients who had a BRAF mutation and were negative for MLH1 promoter methylation pursued testing, and none had a germline MMR mutation. Among the 26 patients who were positive for MLH1 methylation and had wild-type BRAF, 8 pursued testing, and none had an MMR mutation. An individual with germline MLH1 methylation would typically exhibit such a discordant pattern of positive MLH1 methylation and wild-type BRAF in the tumor. One of our patients (no. 14) was positive for an MLH1 germline methylation. This individual had previously been diagnosed with CRC in 2006, and germline MLH1 methylation was recognized at that time. The patient then developed a second colon cancer during the study period; and, according to protocol, IHC was performed on the resected tumor. This sample exhibited loss of MLH1 staining. Because it already was known that the patient had germline MLH1 methylation, no further analysis (including tumor MLH1 methylation, BRAF genotyping, or germline testing) was pursued.
Overall, patients who pursued genetic counseling were significantly younger compared with those who did not (60 6 1.6 vs 73 6 1.5 years; P < .001), and no significant differences were observed between tumor type (EC vs CRC) or type of medical center (primary hospital or tertiary center). An analysis according to sex was not performed because of the sex exclusivity of patients with EC. When the CRC and EC groups were analyzed separately, younger age remained a significant feature for patients with CRC who pursued genetic testing (61 6 1.8 vs 76 6 1.5 years; P < .001), but not for those with EC (56 6 2.6 vs 60 6 2.3 years; P 5 NS). The probability that counseling would be pursued did not differ significantly between the CRC and EC groups based on the type of medical center. Among the patients with CRC, no significant difference was observed in the likelihood of pursuing genetic testing between men and women.
Limitations of Alternative Strategies for Identifying LS Families
To determine whether other measures would have identified the LS families detected by universal screening, we characterized all germline mutation-positive individuals using the Amsterdam criteria, the revised Bethesda criteria, and both the PREMM 1,2,6 model and the recently updated PREMM 5 model. None of these criteria would have detected all of the families identified by universal screening (Tables 2 and 3) . Specifically, 8 patients with CRC and 7 with EC who had LS did not meet Amsterdam II criteria (62.5% of all patients with LS), and 4 patients with CRC and all 8 with EC who had LS did not meet revised Bethesda criteria (50% of all patients with LS). The PREMM 5 model has recently replaced the PREMM 1,2,6, model to better capture individuals who have PMS2 mutations. 10 However, in our population, both the PREMM 1,2,6 and PREMM 5 models would have missed 3 patients with CRC who had PMS2 mutations (18.8% of all patients who had LS with CRC; 12.5% of all patients with LS). Finally, restricting universal screening to patients aged <70 years would have missed 2 Cancer patients with CRC and 1 with EC (12.5% of all patients with LS).
DISCUSSION
In this large, prospective study, we have demonstrated the effectiveness of combining patients who have EC with those who have CRC in a universal screening program for LS. This combined approach increased the overall number of LS diagnoses by 50%. None of the patients who had LS identified in the EC group were related to those in the CRC group, indicating that this expanded screening strategy is not redundant. This is the first real-world, prospective, universal screening program to include both patients with EC and those with CRC in the same population from both a community hospital and a tertiary referral center. Furthermore, EC screening outperformed CRC screening, and this highlights the importance of this expanded approach. Although the limited performance of traditional risk-assessment tools has long been validated, we are the first to report the limitation of even the most recently updated PREMM 5 calculator. Our overall rate of diagnosis of LS (1.4%; 95% CI, 0.9%-2%) is low. In general, published detection rates have ranged an average of 2% to 3% for individuals with either CRC or EC, although there is some variation between different reports. 6, 7, 11, [15] [16] [17] [18] [19] [20] [21] [22] Our detection rate may be lower for several reasons. Only one-half of all patients who were referred for genetic counseling ultimately attended a counseling session. However, it is important to note that most patients who did attend a counseling session pursued genetic testing. It is also possible that the detection of new cases of LS by tumor screening may gradually decline over time, as rigorous cancer screening for individuals previously identified to be at high-risk becomes more common. 23 Nevertheless, LS remains underdiagnosed in the population. With respect to the distribution of the specific mutations in our cohort, there were fewer MSH2 mutations (21% of total) than would be expected. This likely reflects variability within a specific subset of our patient population over a limited study period. Among our entire cohort of greater than 200 previously identified individuals with LS at our institution, MSH2 mutations were indeed the most commonly identified. Thirty-seven percent of our patients with LS carried an MSH2 mutation (personal communication), which is consistent with the published rate of 41%. 7 Despite ongoing efforts to improve the detection of LS, a significant numbers of families remain unidentified. An automated approach to screening is likely to be more effective than 1 that requires active input by clinicians, who often do not obtain a careful family history or have ; and, in our series, all would have missed a significant number of patients identified through universal screening, as did the recently updated PREMM 5 calculator. The 3 patients who were missed by the PREMM 5 model were positive for a PMS2 mutation (which was the second most commonly mutated gene among patients with CRC). The Amsterdam II criteria, revised Bethesda criteria, and both PREMM (PREMM 1,2,6 and PREMM 5 ) calculators would have missed 62.5%, 50%, and 12.5% of the patients diagnosed with LS, respectively. The proposed strategy of limiting screening to those aged <70 years also would have failed to identify 12.5% of patients who had LS, which is an unacceptably high rate. Overall, these findings highlight the observation that LS can be quite heterogeneous clinically; and, ultimately, defining clinical criteria that can effectively identify all patients who have LS may be too challenging.
The performance of a screening program is influenced by the rate of uptake of genetic counseling and testing. Optimizing the uptake rate for genetic testing is a known challenge for genetic screening programs. 23 In our study, just over 50% of those who were referred for genetic counseling attended a counseling session, suggesting that the LS diagnosis rate potentially could double with greater participation. In our population, younger age was the 1 variable associated with attendance at genetic counseling among patients with CRC. Strategies to target the older population need to be developed to address possible age-associated barriers, such as perceived risk, ease of access to counseling, and comorbid illnesses. Although there are important opportunities to improve on this participation rate, it should be noted that, among those who attended counseling, high uptake rates for genetic testing were observed for both patients with EC and those with CRC (97.1% and 79.5%, respectively; P 5 NS). These rates are much higher than those previously reported in screening programs for LS 24 and hereditary breast cancer. 25 It has been demonstrated that screening for LS among all patients with CRC is cost effective. 23, [26] [27] [28] [29] [30] In our large study performed in a real-world setting, screening all patients with EC resulted not only in a smaller proportion of patients referred for genetic counseling but also in a higher mutation-detection rate among those who attended a counseling session compared with the CRC group. Screening all patients with EC appears to be more efficient than screening all patients with CRC, and including patients with EC in screening programs may improve the cost effectiveness of screening for LS overall. The observation that none of the patients identified through EC screening were previously diagnosed with CRC or were related to patients identified through CRC screening underscores the added value of including cancers other than CRC to identify LS families. However, it should be noted that the implementation of such a program will necessarily incur significant up-front costs associated with IHC staining, genetic counseling, and genetic testing. In summary, LS screening programs can be significantly improved by including both CRC and EC, the 2 most common malignancies in LS, and such a strategy will identify patients who are missed even by the most updated clinical calculators.
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